Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest advances in treatment for ALK positive NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 1251

Prof Gordon McVie, Dr Lázaro Quintela

Prof Gordon McVie and Dr Mártin Lázaro Quintela speak at ESMO 2018 in Munich about screening and treatment options for ALK NSCLC patients, and the research presented at this years conference changing practice for clinicians.

Dr Qunitela highlights alectinib data presented at ASCO 2018, and how new research extends its benefit over crizotinib.

Lorlatinib, ceritinb and brigantinib were also reported on at the conference, with the latter showing activity in brain metastases with a response rate of over 80%.

The latest ESMO guidelines recommend alectinib as the first choice to treat ALK lung cancer, and the options for treatment after relapse continue to widen.

ALK-positive NSCLC treatment options in 1L
ALK-positive NSCLC clinical trials presented at ESMO
New ESMO guidelines for ALK-positive NSCLC patients
Brain metastases management

This programme has been supported by Roche.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation